A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

ABSTRACT:

Purpose

For patients with metastatic colorectal cancer (mCRC), no standard therapy exists after progression on 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab. Preclinical data demonstrated that combined vascular endothelial growth factor and mammalian target of rapamycin inhibition has greater antiangiogenic and antitumor activity than either monotherapy. A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC.

Methods

Fifty patients with refractory mCRC were enrolled and received bevacizumab at 10 mg/kg every 2 weeks and everolimus at 10 mg orally daily.

Results

Of the 50 patients enrolled, the median age was 56 years and the median number

SUBMITTER: Altomare I 

PROVIDER: S-EPMC3228156 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature